(HealthDay)—For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to ...
Dec 8, 2020
0
2
(HealthDay)—For the first-line treatment of microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) metastatic colorectal cancer, pembrolizumab is superior to chemotherapy for prolonging progression-free ...
Dec 3, 2020
0
0
(HealthDay)—A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet.
Nov 18, 2020
0
4
(HealthDay)—For patients with non-small cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression, treatment with atezolizumab results in longer overall survival than chemotherapy, according to a study ...
Oct 1, 2020
0
1
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer. This is the finding of the long-term analyses of an international phase ...
Sep 29, 2020
0
9
(HealthDay)—For patients with advanced urothelial cancer treated with atezolizumab, proton pump inhibitor (PPI) use is a negative prognostic marker, according to a study published online Sept. 15 in Clinical Cancer Research.
Sep 16, 2020
0
5
New treatment options for people with advanced or unresectable hepatocellular carcinoma (HCC) may now be a step closer after three research groups presented safety and efficacy data at the Digital International Liver Congress ...
Aug 28, 2020
0
2
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients ...
Aug 8, 2020
0
2
The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic ...
Aug 8, 2020
0
1
(HealthDay)—For patients with diffuse large B-cell lymphoma (DLBCL), the combination of low muscle mass (LMM) and low muscle density (LMD) is an independent prognostic factor for survival, according to a study published ...
Jul 28, 2020
0
1
